Navigation Links
Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010

Merrimack Pharmaceuticals, Inc. announced today that Clet Niyikiza, Ph.D., Executive Vice President of Development, will present at the BioVisionAlexandria 2010 conference as part of the panel, titled Cancer Care and Prevention: Novel Approaches.

Cambridge, MA (PRWEB) April 14, 2010 -- Clet Niyikiza, Ph.D., Executive Vice President of Development at Merrimack Pharmaceuticals, Inc., will present at the BioVisionAlexandria 2010 conference in Alexandria, Egypt.

The theme of this year’s fifth international biennial conference, put on by BioVision Alexandria, is New Life Sciences: Future Prospects. The goal of the conference is to get the greatest minds in industry, science, policy-making and civil society to identify and explore key areas in the field of life sciences that have the potential to serve a number of people across continents and cultures. Also featured in the conference is a Nobel Day where recipients of the Nobel Prize discuss the impact of their work and their future vision for the life sciences industry.

Dr. Niyikiza is speaking as part of a panel discussion in the Health portion of the conference which is built around the three major themes of Health, Food and Agriculture and Environment. The panel, titled Cancer Care and Prevention: Novel Approaches, takes place on Wednesday, April 14 from 3:30pm – 5:00pm.

About Merrimack
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery and development of novel medicines for the treatment of cancer and inflammation. The Company is advancing a robust pipeline of engineered therapeutics paired with molecular diagnostics. Merrimack’s first two oncology candidates, MM-121, partnered with sanofi-aventis, and MM-111, are in Phase 1 clinical testing with multiple pre-clinical development and research stage programs in the pipeline. MM-121 and MM-111 are investigational drugs and have not been approved by the U.S. Food and Drug Administration or any international regulatory agency. The Company’s proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, integrates the fields of engineering, biology and computing to enable mechanism-based model driven discovery and development of both therapeutics and diagnostics. Merrimack is a privately-held company based in Cambridge, Massachusetts. For additional information, please visit

Contact: Kathleen Petrozzelli, Corporate Communications, 617-441-1043, Betsy Raymond Stevenson, 860-984-1424, RaymondStevenson Healthcare Comms


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development
2. Merrimack Pharmaceuticals Recognized for Innovative Talent Management in HR Executive Magazine's ‘Best HR Ideas for 2010' Issue
3. UPDATE: Appeal of Lawsuit by Former Chief Executive Officer- Reinstated; and Sanctions Order Vacated
4. Appeal of Lawsuit by Former Chief Executive Officer- Reinstated; and Sanctions Order Vacated
5. BioSoteria eLearning Executive Michelle Flewell Selected for Accreditation Council
6. FMC Agricultural Products Executive Bob Trogele Speaks to the Iowa Agribusiness Showcase & Conference
7. Amicus Therapeutics Board of Directors Names Chief Executive Officer John F. Crowley Chairman of the Board
8. Fibrocell Science, Inc. Names David Pernock Chief Executive Officer
9. Glycos Biotechnologies Appoints Chief Executive Officer
10. Biofuels Technology Leader Qteros Names Industry Veteran John McCarthy President and Chief Executive Officer
11. Marrone Bio Innovations Announces Two New Executive Appointments
Post Your Comments:
Related Image:
Clet Niyikiza, Merrimack's Executive Vice President of Development, to Present at BioVisionAlexandria 2010
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016 On Monday, the ... to industry to share solutions for the Biometric Exit ... Customs and Border Protection (CBP), explains that CBP intends ... departing the United States , in ... to defeat imposters. Logo - ...
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
Breaking Biology News(10 mins):